Logo Logo
Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Jump to: 2017 | 2016
Number of items: 3.

2017

Al-Sawaf, O.; Robrecht, S.; Bahlo, J.; Fink, A. M.; Cramer, P.; Tresckow, J. von; Maurer, C.; Bergmann, M.; Seiler, T.; Lange, E.; Kneba, M.; Stilgenbauer, S.; Döhner, H.; Kiehl, M. G.; Jäger, U.; Wendtner, C. M.; Fischer, K.; Göde, V.; Hallek, M.; Eichhorst, B.; Hopfinger, G. (2017): Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. In: Leukemia, Vol. 31, No. 10: pp. 2251-2253

Cramer, P.; Tresckow, J. von; Bahlo, J.; Robrecht, S.; Al-Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.-M.; Fischer, K.; Tausch, E.; Seiler, T.; Fischer von Weikersthal, L.; Hebart, H.; Kreuzer, K.-A.; Ritgen, M.; Kneba, M.; Wendtner, C.-M.; Stilgenbauer, S.; Eichhorst, B.; Hallek, M. (2017): Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG). In: Oncology Research and Treatment, Vol. 40: p. 24

2016

Al-Sawaf, O.; Kluth, S.; Bahlo, J.; Hopfinger, G.; Fink, A. M.; Cramer, P.; Maurer, C.; Bergmann, M.; Dreyling, M.; Lange, E.; Kneba, M.; Stilgenbauer, S.; Kiehl, M. G.; Jäger, U.; Wendtner, C. M.; Fischer, K.; Hallek, M.; Eichhorst, B. (2016): Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). In: Oncology Research and Treatment, Vol. 39: pp. 212-213

This list was generated on Mon May 27 04:52:39 2019 CEST.